Prospective Grant of Exclusive License: Therapeutic Uses of Microtubule Stabilizing Agents Including Taxol (Paclitaxel) for Fibroproliferative Vascular Diseases Including Atherosclerosis and Restenosis and Excluding Cancer

Riepilogo

This is notice in accordance with 15 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a worldwide, limited field of use, exclusive license to practice the inventions embodied in the patents and patent applications referred to below to Angiotech Pharmaceuticals Inc. of Vancouver, British Columbia, Canada. The patent rights in these inventions have been assigned to the government of the United States of America. The patents and patent applications to be licensed are: ``Methods of Treating Atherosclerosis or Restenosis Using Microtubule Stabilizing Agent,'' U.S. Patent Application Serial No. 08/099,067 filed July 29, 1993; and all continuation applications, divisional applications, continuation-in- part applications, and foreign counterpart applications related to U.S. Patent Application Serial No. 08/099,067. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within ninety (90) days with the date of this published notice, NIH receiv